Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Introduction Of Biosimilar Therapeutics Into Nephrology Practice In The United States: Report Of A Scientific Workshop Sponsored By The National Kidney Foundation, Jay B. Wish, Chaim Charytan, Glenn M. Chertow, Kamyar Kalantar-Zadeh, Alan S. Kliger, Robert J. Rubin, Jerry Yee, Steven Fishbane
Introduction Of Biosimilar Therapeutics Into Nephrology Practice In The United States: Report Of A Scientific Workshop Sponsored By The National Kidney Foundation, Jay B. Wish, Chaim Charytan, Glenn M. Chertow, Kamyar Kalantar-Zadeh, Alan S. Kliger, Robert J. Rubin, Jerry Yee, Steven Fishbane
Nephrology Articles
Biosimilars are biologic medicines highly similar to the reference product with no meaningful clinical differences in terms of safety, purity, and potency. All biologic medicines are produced by living cells, resulting in an inherent heterogeneity in their higher order structures and post-translational modifications. In 2010, the US Congress enacted legislation to streamline the approval process for biosimilars of products losing patent protection, with the goal of decreasing costs and improving patient access to therapeutically important but expensive biologic agents. In 2015, the US Food and Drug Administration approved the first biosimilar agent through this pathway. Approval of additional biosimilar agents …
Geriatric Ckd: Value-Based Nephrology, Jerry Yee
Geriatric Ckd: Value-Based Nephrology, Jerry Yee
Nephrology Articles
No abstract provided.